Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 316310, 6 pages
http://dx.doi.org/10.1155/2014/316310
Research Article

A New Nested Allele-Specific Multiplex Polymerase Chain Reaction Method for Haplotyping of VKORC1 Gene to Predict Warfarin Sensitivity

1Department of Pharmacology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
2Department of Haematology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
3Invasive Cardiology Laboratory, Hospital Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
4Human Genome Center, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia

Received 26 December 2013; Revised 23 February 2014; Accepted 25 February 2014; Published 30 March 2014

Academic Editor: Stelvio M. Bandiera

Copyright © 2014 Yung An Chua et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. K. Higashi, D. L. Veenstra, L. Midori Kondo et al., “Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy,” Journal of the American Medical Association, vol. 287, no. 13, pp. 1690–1698, 2002. View at Google Scholar · View at Scopus
  2. D. L. Veenstra, J. H. S. You, M. J. Rieder et al., “Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population,” Pharmacogenetics and Genomics, vol. 15, no. 10, pp. 687–691, 2005. View at Google Scholar · View at Scopus
  3. M. D. Caldwell, R. L. Berg, Q. Z. Kai et al., “Evaluation of genetic factors for warfarin dose prediction,” Clinical Medicine and Research, vol. 5, no. 1, pp. 8–16, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Zhu, M. Shennan, K. K. Reynolds et al., “Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes,” Clinical Chemistry, vol. 53, no. 7, pp. 1199–1205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Lenzini, M. Wadelius, S. Kimmel et al., “Integration of genetic, clinical, and INR data to refine warfarin dosing,” Clinical Pharmacology and Therapeutics, vol. 87, no. 5, pp. 572–578, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. Maryland: US Food and Drug Administration, FDA approves updated warfarin (Coumadin) prescribing information: New genetic Information may help providers improve initial dosing estimates of the anticoagulant for individual patients, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108967.htm.
  7. T. Li, C.-Y. Chang, D.-Y. Jin, P.-J. Lin, A. Khvorova, and D. W. Stafford, “Identification of the gene for vitamin K epoxide reductase,” Nature, vol. 427, no. 6974, pp. 541–544, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Rost, A. Fregin, V. Ivaskevicius et al., “Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2,” Nature, vol. 427, no. 6974, pp. 537–541, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. M. J. Rieder, A. P. Reiner, B. F. Gage et al., “Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose,” The New England Journal of Medicine, vol. 352, no. 22, pp. 2285–2293, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. S.-C. Lee, S.-S. Ng, J. Oldenburg et al., “Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population,” Clinical Pharmacology and Therapeutics, vol. 79, no. 3, pp. 197–205, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. L.-S. Tham, B.-C. Goh, A. Nafziger et al., “A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9,” Clinical Pharmacology and Therapeutics, vol. 80, no. 4, pp. 346–355, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. G. D'Andrea, R. L. D'Ambrosio, P. di Perna et al., “A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin,” Blood, vol. 105, no. 2, pp. 645–649, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. H.-Y. Yuan, J.-J. Chen, M. T. M. Lee et al., “A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity,” Human Molecular Genetics, vol. 14, no. 13, pp. 1745–1751, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. E. A. Sconce, T. I. Khan, H. A. Wynne et al., “The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen,” Blood, vol. 106, no. 7, pp. 2329–2333, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Rai, N. Udar, R. Saad, and M. Fleisher, “A multiplex assay for detecting Genetic variations in cyp2c9, vkorc1, and GGCX involved in warfarin metabolism,” Clinical Chemistry, vol. 55, no. 4, pp. 823–826, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M. J. Rieder, A. P. Reiner, and A. E. Rettie, “γ-Glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose,” Journal of Thrombosis and Haemostasis, vol. 5, no. 11, pp. 2227–2234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Miyagata, K. Nakai, and Y. Sugiyama, “Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin,” International Heart Journal, vol. 52, no. 1, pp. 44–49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Howard, J. B. S. Leathart, D. J. French et al., “Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon probes,” Clinica Chimica Acta, vol. 412, no. 23-24, pp. 2063–2069, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. S.-W. Huang, Q. Li, S.-Y. Zhu et al., “SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement,” Clinical Chemistry and Laboratory Medicine, vol. 47, no. 1, pp. 26–31, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Kosaki, C. Yamaghishi, R. Sato et al., “1173C>T polymorphism in VKORC1 modulates the required warfarin dose,” Pediatric Cardiology, vol. 27, no. 6, pp. 685–688, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. Z. Zainuddin, L. K. Teh, A. W. M. Suhaimi, and R. Ismail, “Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphism,” Journal of Clinical Pharmacy and Therapeutics, vol. 31, no. 2, pp. 187–191, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. K. C. Seng, G. G. Gin, J. V. Sangkar, and M. E. Phipps, “Frequency of cytochrome P450 2C9 (CYP2C9) alleles in three ethnic groups in Malaysia,” Asia-Pacific Journal of Molecular Biology and Biotechnology, vol. 11, no. 2, pp. 83–91, 2003. View at Google Scholar · View at Scopus
  23. G. G. Gan, M.-T. M. Lee, R. Subramaniam, L.-S. Lu, M. C. Tai, and M. E. Phipps, “Allele and genotype frequencies of VKORC1 -1639g > a polymorphism in three different ethnic groups in Malaysia,” Asia-Pacific Journal of Molecular Biology and Biotechnology, vol. 20, no. 1, pp. 19–23, 2012. View at Google Scholar · View at Scopus